The most frequently cited concerns included hypoglycemia (both GLP-RAs and SGLT2 inhibitors), urinary tract infections (SGLT2 inhibitors), diabetic ketoacidosis (both GLP-RAs and SGLT2 inhibitors), and other potential side effects [90]. The gene discussed is SLC5A2; the disease is Hypoglycemia.